<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300131</url>
  </required_header>
  <id_info>
    <org_study_id>05-370</org_study_id>
    <nct_id>NCT00300131</nct_id>
  </id_info>
  <brief_title>ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation</brief_title>
  <acronym>ABSORB A</acronym>
  <official_title>Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-labeled First in Man Clinical Investigation enrolling patients with
      visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x
      18 mm BVS EECSS containing 98 microgramme per cm² of surface area.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, open-labeled Clinical Investigation enrolling patients with visually
           estimated nominal vessel diameter of 3.0 mm and lesion length ≥ 8 mm receiving a single
           3.0 x 12 mm BVS Everolimus Eluting CSS containing 98 microgramme per cm² of surface
           area. Lesion length will be expanded to≥ 14 mm in length by visual estimation when 3.0 x
           18 mm stent is available.

        -  Angiographic, Intravascular Ultrasound (IVUS), Intravascular Ultrasound- virtual
           histology (IVUS-VH) and Palpography follow-up will be carried out in all patients at 180
           days and 2 years following the index procedure

        -  Optical Coherence Tomography (OCT) follow-up at 180 days and 2 years will be carried out
           in a subset of up to 10 patients in Cohorts A and B respectively who are enrolled in
           pre-determined clinical site(s)

        -  Multi-slice Spiral Computed Tomography (MSCT) is an optional procedure which may be
           carried out at 18 months post procedure and again between 4 and 5 year follow up.

        -  Additionally, coronary vasomotion test may be done at 2 years post procedure

      Single patient Cohort of 30.

      Pipeline products. Currently in development at Abbott Vascular. Not available for sale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemia Driven MACE</measure>
    <time_frame>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years;</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemia driven Target Vessel Failure (TVF)</measure>
    <time_frame>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years;</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute success (clinical device and clinical procedure)</measure>
    <time_frame>Acute</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>at 30, 180, 270 days and 1, 2, 3, 4, 5 years;</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>at 30, 180, 270 days and 1, 2, 3, 4, 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent Late Loss(LL)</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment LL</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal LL (proximal defined as within 5 mm of tissue proximal to stent placement)</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal LL (distal defined as within 5 mm of tissue distal to stent placement)</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment Angiographic Binary Restenosis (ABR) rate</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent % Volume Obstruction (VO)</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting incomplete apposition, late incomplete apposition, aneurysm, thrombus, persisting dissection</measure>
    <time_frame>at 180 days and 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioabsorbable Everolimus Eluting Coronary Stent</intervention_name>
    <description>Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease</description>
    <arm_group_label>1</arm_group_label>
    <other_name>BVS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Target lesion must be located in a native epicardial vessel with visually estimated nominal
        vessel diameter of 3.0 mm

          -  Target lesion must measure less/equal 8 mm in length by visual estimation for 3.0 x 12
             mm, expanded to less/equal 14 mm in length by visual estimation when 3.0 x 18 mm stent
             is available

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of &gt; 50% and &lt; 100% with a TIMI flow of greater/equal 1

          -  Non-Clinical Investigation, percutaneous intervention for lesions in a non-target
             vessel is allowed if done more/equal 90 days prior to or if planned to be done 6
             months after the index procedure

          -  Non-Clinical Investigation, percutaneous intervention for lesions in the target vessel
             is allowed if done &gt; 6 months prior to or if planned to be done 6 months after the
             index procedure

        Exclusion Criteria:

          -  Located within an arterial or saphenous vein graft or distal to a diseased (defined as
             vessel irregularity per angiogram and &gt; 20% stenosed lesion by visual estimation)
             arterial or saphenous vein graft

          -  Lesion involving a bifurcation greater/equal 2 mm in diameter and ostial lesion &gt; 40%
             stenosed by visual estimation or side branch requiring predilatation

          -  Total occlusion (TIMI flow 0), prior to wire passing

          -  The target vessel contains visible thrombus

          -  Another clinically significant lesion is located in the same epicardial vessel
             (including side branch) as the target lesion

          -  Patient has received brachytherapy in any epicardial vessel (including side branches)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ormiston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Serruys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus University Thorax Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>France</country>
  </removed_countries>
  <reference>
    <citation>Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007 Jan;69(1):128-31.</citation>
    <PMID>17139655</PMID>
  </reference>
  <reference>
    <citation>TCT Daily: ABSORB: bioabsorbable coronary stents successfully and safely deployed. J Interv Cardiol. 2007 Feb;20(1):36-7.</citation>
    <PMID>17300400</PMID>
  </reference>
  <results_reference>
    <citation>Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007 Oct 1;70(4):515-23.</citation>
    <PMID>17503509</PMID>
  </results_reference>
  <results_reference>
    <citation>Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008 Mar 15;371(9616):899-907. doi: 10.1016/S0140-6736(08)60415-8.</citation>
    <PMID>18342684</PMID>
  </results_reference>
  <results_reference>
    <citation>Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009 Mar 14;373(9667):897-910. doi: 10.1016/S0140-6736(09)60325-1.</citation>
    <PMID>19286089</PMID>
  </results_reference>
  <results_reference>
    <citation>García-García HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention. 2009 Jan;4(4):443-8.</citation>
    <PMID>19284065</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanimoto S, Bruining N, van Domburg RT, Rotger D, Radeva P, Ligthart JM, Serruys PW. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008 Nov 11;52(20):1616-20. doi: 10.1016/j.jacc.2008.08.024.</citation>
    <PMID>18992650</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruining N, Tanimoto S, Otsuka M, Weustink A, Ligthart J, de Winter S, van Mieghem C, Nieman K, de Feyter PJ, van Domburg RT, Serruys PW. Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2- and 3D-QCA, QCU and QMSCT-CA. EuroIntervention. 2008 Aug;4(2):285-91.</citation>
    <PMID>19110796</PMID>
  </results_reference>
  <results_reference>
    <citation>Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009 Jun;2(3):255-60. doi: 10.1161/CIRCINTERVENTIONS.109.859173. Review.</citation>
    <PMID>20031723</PMID>
  </results_reference>
  <results_reference>
    <citation>Macaya C, Moreno R. Bioabsorbable drug-eluting stents: the future of coronary angioplasty? Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):598-9. doi: 10.1038/ncpcardio1306. Epub 2008 Aug 5.</citation>
    <PMID>18679382</PMID>
  </results_reference>
  <results_reference>
    <citation>Onuma Y, Piazza N, Ormiston JA, Serruys PW. Everolimus-eluting bioabsorbable stent--Abbot Vascular programme. EuroIntervention. 2009 Dec 15;5 Suppl F:F98-F102. doi: 10.4244/EIJV5IFA17. Review.</citation>
    <PMID>22100687</PMID>
  </results_reference>
  <results_reference>
    <citation>Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009 Dec 15;5 Suppl F:F15-22. doi: 10.4244/EIJV5IFA3. Review.</citation>
    <PMID>22100671</PMID>
  </results_reference>
  <results_reference>
    <citation>Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010 Nov 30;122(22):2288-300. doi: 10.1161/CIRCULATIONAHA.109.921528. Epub 2010 Oct 25.</citation>
    <PMID>20975003</PMID>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioabsorbable</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Everolimus</keyword>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>angioplasty</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>total coronary occlusion</keyword>
  <keyword>coronary artery restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>vascular disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

